Seeking Alpha
18 Nov 2026, 04:12 UTC · 59m ago
Precigen: Upgrading To Buy As Competitive Fears Over VOCERYQ Look Overblown
Impact · against what's priced in
Precigen's strong Q3 revenue growth and accelerated cash flow positivity provide positive fundamental momentum. The primary catalyst is the argument that competitive fears regarding VOCERYQ are overblown, suggesting the market has over-discounted the stock's valuation.
- PGEN+0.40
No priced-in read yet
- In context
PAPZIMEOS sequential revenue growth of 37% to $72.9 million and positive operating cash flow ahead of guidance suggest an operational beat. Furthermore, the claim that the market has overreacted to VOCERYQ's approval provides a valuation catalyst toward a modeled $7.01 price target.
Read from the article alone





